Our Investment in Perceptic: The AI Operating System for Drug Discovery and Development
Summary
- Drug discovery remains a multi-year, siloed process where proprietary data lives in disconnected systems, causing insights to die at every handoff.
- Most AI tools in pharma only optimize individual workflows while leaving silos intact, whereas Perceptic functions as a mission control AI operating system for the full drug lifecycle.
- Perceptic connects asset scouting, scientific evaluation, & clinical data to allow teams to follow the drug rather than the department.
- Live deployments have cut scientific due diligence from weeks to hours, scaled asset screening from hundreds to thousands per week, & increased clinical data extraction by 50-fold.
- The platform is already deployed at top-ten pharma companies, biotechs, & CROs, including CSL.
- Founders Tilman Flock, Martin Copes, & Zaki Trache previously built Palantir's AI Platform & Life Sciences practice.
- The team aims to create a self-improving platform where insights compound on previous decisions within highly regulated environments.
- Perceptic secured a $12M seed round led by the author alongside Air Street Capital & Elder Gull.
Drug discovery and development today remains a multi-year, deeply siloed process. Pharmaceutical companies have spent decades accumulating proprietary research, clinical data, and institutional knowledge—yet most of it remains effectively invisible. It lives inside systems that were never designed to talk to each other, accessed by teams that were never designed to collaborate. Critical decisions are made without the full picture because, as Perceptic CEO Tilman Flock puts it: "That's a linear process where insight dies at every handoff."